Arcutis Biotherapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on developing and commercializing innovative therapies for dermatological diseases. Founded in 2016 and headquartered in Westlake Village, California, Arcutis concentrates on delivering novel topical treatments that address key unmet needs in cutaneous disorders. The company’s scientific approach emphasizes targeting molecular pathways implicated in inflammatory skin conditions, leveraging both small molecules and advanced formulation technologies to enhance efficacy, safety and patient adherence.
A core component of Arcutis’ portfolio is its roflumilast cream program, which includes an approved topical formulation for plaque psoriasis. This product, marketed under the brand name ZORYVE, represents the company’s first commercial launch and underscores its capacity to navigate the regulatory process through the U.S. Food and Drug Administration (FDA). In parallel, the roflumilast cream is under clinical investigation for additional indications such as seborrheic dermatitis, a common inflammatory condition of the skin and scalp.
Beyond roflumilast, Arcutis is advancing a robust pipeline of proprietary candidates. ARQ-151 is a novel foam formulation of roflumilast designed specifically for scalp psoriasis, while ARQ-154 is being explored for atopic dermatitis. The company is also developing ARQ-252, a selective topical Janus kinase 1 (JAK1) inhibitor targeting chronic hand and foot eczema. These programs reflect Arcutis’ commitment to expanding its therapeutic scope and addressing a diverse array of dermatological disorders with high unmet medical need.
Under the leadership of President and Chief Executive Officer Jerry McLaughlin, Arcutis has built an experienced management team with deep expertise in dermatology, biopharmaceutical development and commercial operations. The company maintains strategic collaborations with contract research organizations, manufacturing partners and distribution networks across North America. Arcutis continues to pursue both domestic growth and potential international expansion, positioning itself to become a leading specialty dermatology company by bringing new, targeted treatments to patients worldwide.
AI Generated. May Contain Errors.
Free ARQT Stock Alerts